The efficacy of bi-specific antibodies in treating lymphoma

Bi-specific T cell engaging antibodies, such as glofitomab, epratuzumab, and mocinatumab, have shown promising results in the treatment of lymphoma. These antibodies target CD3 and CD20, leading to T-cell activation and subsequent death of the target B-cells. They have demonstrated overall response rates of around 70% and complete remission rates of approximately 60% in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients. Transformed follicular lymphoma and other aggressive subtypes of lymphoma have also shown positive responses to these bi-specific antibodies. Additionally, some early data suggests that mantle cell lymphoma may also benefit from this treatment approach. While there are some differences in efficacy and toxicity profiles among the different bi-specific antibodies, they all hold potential as effective treatment options for lymphoma.